Neuro-Bio Ltd appoints Dr. Alex Wilson as Development Director
Oxford, UK; March 2019 – Neuro-Bio Ltd, a UK-based early stage biopharmaceutical company that focuses on a novel approach to treating Alzheimer’s Disease, today announced that it has appointed Dr. Alex Wilson as its new Development Director.
Dr Wilson graduated from the University of Bradford, with a PhD in Psychopharmacology, followed by a 2-year post doc in Parkinson’s Disease at Hammersmith Hospital, utilizing a prototypical small animal PET scanner. He then spent 10 years working in Research and Development at SmithKline Beecham and GlaxoSmithKline, Neuroscience and Neurology centers. In 2007 Dr Wilson moved to Singapore to set up translational medicine capabilities of an SME, CRO, during this time he progressed through C-suite roles in the organisation, and completed an MBA from the University of Chicago, Booth School of Business. Before joining Neuro-Bio, he was the Managing Director for a privately-owned SME in Singapore that focused on in-vitro diagnostic device development using a proprietary affinity reagent approach.
Neuro-Bio’s CEO, Baroness Professor Susan Greenfield said “Now that Neuro-Bio is evolving into a larger company and making the transition from Research to Development in both our biomarker and therapeutic programs, the expertise that Dr Wilson is bringing could not be timelier. We were impressed, not only by his broad pharmaceutical experience, unusually with both biomarker and drug discovery areas, but also by his commercial qualifications. This profile is the perfect fit for ensuring that Neuro-Bio can realise its full potential in progressing towards realistic products for an effective diagnosis and treatment for Alzheimer’s Disease.”
Lord Arbuthnot, Chairman of Neuro-Bio, said, “We are really pleased to welcome Alex to his new role. He brings us the combination of big pharma and SME experience that is exactly what we need at our current stage of development. We have promising data sets showing the effects of a potential therapeutic molecule at a basic research level that may block or significantly retard the progression of the AD pathology. And using the same molecular motifs we have demonstrated a correlation of this structure in blood with CNS pathology, potentially leading to a biomarker / diagnostic. We need to take these highly promising outcomes and translate them into a package of data and reports which, along with other studies, will allow us to provide a regulatory submission for an IND and IVD, respectively. Alex will be ideally placed to take us on this important journey.”
Dr. Wilson said “I am delighted to be able contribute to the work that Neuro-Bio is pioneering. In an era where mankind is living longer, conditions impacting an ever-aging population will only increase in importance. As such, degenerative conditions like Alzheimer’s that rob families of their loved ones well before the end of their natural lives will become more burdensome, both financially and emotionally. Neuro-Bio offers as radical new approach both to early detection and diagnosis, as well as therapeutic intervention, well in advance of the profound neuronal loss and cognitive sequalae that become apparent as the disease progresses. I join the company at an incredibly exciting time when we need to focus our efforts on implementing the preclinical plans that will form the most critical part of our pipeline efforts leading to regulatory submissions”
Dr. Wilson’s pharmaceutical career started at SmithKline Beecham in 1998 where he was a member of the team evaluating pharmacodynamic markers of drug action across the Neuroscience spectrum. Dr. Wilson then moved to the Pain and Epilepsy disease areas in 2000, on the formation of GlaxoSmithKline where he ran various research programs spanning the spectrum of Gene-To-Target, through to Candidate Selection. He was also central to several post candidate selection efforts leading through to clinical trial evaluation. In 2007 Dr. Wilson began development of a translation model platform for a Singapore-based CRO focusing on non-human primate models of disease that spanned the key areas of focus for current medicine, including state of the art molecular imaging capabilities.
Neuro-Bio Ltd (www.neuro-bio.com) is an early stage biopharmaceutical company that is developing novel, effective therapies for neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Motor Neuron diseases. The company was founded in 2013 by Baroness Professor Susan Greenfield based on 40 years of original neuroscience research leading to an exclusive and proprietary approach to developing therapies to arrest the progress of these CNS disorders.